Alyea Edwin P
Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 01770, USA.
Best Pract Res Clin Haematol. 2008 Jun;21(2):239-50. doi: 10.1016/j.beha.2008.02.012.
Graft-versus-host disease (GVHD) has been linked with a potent anti-cancer effect referred to as the graft-versus-leukemia (GVL) or graft-versus-malignancy effect. In some experimental models these processes may be distinct, but in clinical practice they are very closely linked. Induction of GVHD using donor lymphocyte infusion has been used to treat relapse after transplantation. Modulation of GVHD has been explored as a method to reduce the risk of relapse after transplantation. Methods explored include altering GVHD prophylaxis after transplant, selection of peripheral-blood stem cells, prophylactic donor lymphocyte infusion, and use of cytokines. Given the toxicity associated with GVHD, defining the balance between GVHD and induction of GVL is of critical importance in transplantation. Laboratory efforts to identify the targets of GVHD and GVL may allow for more specific and effective therapies to be developed while minimizing toxicity.
移植物抗宿主病（GVHD）与一种强大的抗癌效应相关，即移植物抗白血病（GVL）或移植物抗肿瘤效应。在一些实验模型中，这些过程可能是不同的，但在临床实践中它们紧密相连。使用供体淋巴细胞输注诱导GVHD已被用于治疗移植后的复发。调节GVHD已被探索作为降低移植后复发风险的一种方法。探索的方法包括改变移植后的GVHD预防措施、选择外周血干细胞、预防性供体淋巴细胞输注以及使用细胞因子。鉴于与GVHD相关的毒性，确定GVHD与GVL诱导之间的平衡在移植中至关重要。通过实验室努力识别GVHD和GVL的靶点，可能会开发出更具特异性和有效性的疗法，同时将毒性降至最低。
